title: Prognostic significance of Lewis y antigen in resected stage I and II non-small cell lung cancer.
abstract: BACKGROUND
  The role of Lewis y (Le(y)) antigen expression has been studied extensively in predicting the outcome of various malignancies. We evaluated the expression of Le(y) and its relationship to survival, disease-free survival and other clinicopathologic variables in patients with stage I and II non-small cell lung cancer (NSCLC).
  
  
  OBJECTIVE
  To investigate the prognostic significance of Le(y) antigen expression in a large group of well characterized patients with resected stage I and II NSCLC.
  
  
  METHODS
  Two hundred and sixty patients with surgically resected stage I (n = 193) and II (n = 67) NSCLC with at least 5-year follow-up were identified.
  
  
  RESULTS
  The median survival for patients with negative expression of Le(y) (< 50% of cells that were positive) was 46 months, whereas for those with positive expression of Le(y) (> or = 50%), the median survival was 54 months (p = 0.99). The disease-free survival for patients with Le(y)(-) expression was 39 months and 34 months for patients with Le(y)(+) expression (p = 0.3).
  
  
  CONCLUSIONS
  We found no relationship between loss of blood group antigen A and expression of Le(y). No statistically significant difference was found in survival between positive and negative expression of Le(y) antigen in patients with resected stage I and II NSCLC.
authors.affiliation: Department of Medicine, Veterans Affairs Medical Center and State University of New York-Health Science Center, Syracuse 13210, USA.
authors.forename: S A
authors.initials: SA
authors.lastname: Mehdi
authors.forename: A H
authors.initials: AH
authors.lastname: Tatum
authors.forename: N B
authors.initials: NB
authors.lastname: Newman
authors.forename: A
authors.initials: A
authors.lastname: Imperato
authors.forename: J
authors.initials: J
authors.lastname: Daucher
authors.forename: L J
authors.initials: LJ
authors.lastname: Kohman
authors.forename: S L
authors.initials: SL
authors.lastname: Graziano
mesh_terms: D000017:ABO Blood-Group System; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology / Q000401:mortality* / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007983:Lewis Blood Group Antigens / Q000032:analysis*; D008175:Lung Neoplasms / Q000276:immunology / Q000401:mortality* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D015996:Survival Rate
chemical_list: D000017:ABO Blood-Group System; D014408:Biomarkers, Tumor; D007983:Lewis Blood Group Antigens; C094162:Lewis Y antigen